Pulmonxcorp Stock Performance
| LUNG Stock | USD 9.82 0.44 4.69% |
The company holds a Beta of 1.92, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PulmonxCorp will likely underperform. PulmonxCorp has an expected return of -0.48%. Please make sure to check PulmonxCorp potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if PulmonxCorp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PulmonxCorp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return 4.69 | Five Day Return 34.52 | Year To Date Return (22.68) | Ten Year Return (75.02) | All Time Return (75.02) |
1 | Disposition of 20000 shares by Glendon French of PulmonxCorp at 14.6 subject to Rule 16b-3 | 02/15/2024 |
2 | Pulmonx Corp Reports Solid Revenue Growth Amidst Increased Operating Expenses | 02/21/2024 |
3 | Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal en el ensayo pivotal CONVERT II | 02/27/2024 |
4 | Acquisition by David Lehman of 34500 shares of PulmonxCorp subject to Rule 16b-3 | 03/05/2024 |
5 | Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635 | 03/15/2024 |
6 | AI Learns to Spot COVID-19 in Lung Ultrasound Images | 03/21/2024 |
7 | Disposition of 1184 shares by Geoffrey Rose of PulmonxCorp at 9.36 subject to Rule 16b-3 | 03/22/2024 |
8 | Insider Trading | 04/03/2024 |
9 | Disposition of 1760 shares by Geoffrey Rose of PulmonxCorp at 11.48 subject to Rule 16b-3 | 04/09/2024 |
10 | Disposition of 254 shares by John McKune of PulmonxCorp at 9.06 subject to Rule 16b-3 | 04/19/2024 |
11 | Disposition of 1184 shares by Geoffrey Rose of PulmonxCorp at 7.49 subject to Rule 16b-3 | 04/22/2024 |
12 | Pulmonx Reports First Quarter 2024 Financial Results | 05/01/2024 |
13 | Canaccord Genuity lowers target for Pulmonx shares, reamains bullish on solid Q1 results | 05/02/2024 |
| Begin Period Cash Flow | 102 M |
PulmonxCorp |
PulmonxCorp Relative Risk vs. Return Landscape
If you would invest 1,431 in PulmonxCorp on February 5, 2024 and sell it today you would lose (449.00) from holding PulmonxCorp or give up 31.38% of portfolio value over 90 days. PulmonxCorp is currently does not generate positive expected returns and assumes 4.588% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than PulmonxCorp, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PulmonxCorp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PulmonxCorp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PulmonxCorp, and traders can use it to determine the average amount a PulmonxCorp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1054
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LUNG |
Estimated Market Risk
| 4.59 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PulmonxCorp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PulmonxCorp by adding PulmonxCorp to a well-diversified portfolio.
PulmonxCorp Fundamentals Growth
PulmonxCorp Stock prices reflect investors' perceptions of the future prospects and financial health of PulmonxCorp, and PulmonxCorp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PulmonxCorp Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | 303.85 M | ||||
| Shares Outstanding | 38.81 M | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 4.46 X | ||||
| Revenue | 68.67 M | ||||
| Gross Profit | 39.87 M | ||||
| EBITDA | (59.99 M) | ||||
| Net Income | (60.84 M) | ||||
| Cash And Equivalents | 162.09 M | ||||
| Cash Per Share | 4.35 X | ||||
| Total Debt | 41.42 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.43 X | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | (37.61 M) | ||||
| Earnings Per Share | (1.60) X | ||||
| Market Capitalization | 381.13 M | ||||
| Total Asset | 178.95 M | ||||
| Retained Earnings | (411.16 M) | ||||
| Working Capital | 127.27 M | ||||
About PulmonxCorp Performance
To evaluate PulmonxCorp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when PulmonxCorp generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare PulmonxCorp Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand PulmonxCorp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents PulmonxCorp's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 333.53 | 250.92 | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.51) | (0.49) |
Things to note about PulmonxCorp performance evaluation
Checking the ongoing alerts about PulmonxCorp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PulmonxCorp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PulmonxCorp generated a negative expected return over the last 90 days | |
| PulmonxCorp has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 68.67 M. Net Loss for the year was (60.84 M) with profit before overhead, payroll, taxes, and interest of 39.87 M. | |
| PulmonxCorp currently holds about 162.09 M in cash with (37.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.35. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Canaccord Genuity lowers target for Pulmonx shares, reamains bullish on solid Q1 results |
- Analyzing PulmonxCorp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PulmonxCorp's stock is overvalued or undervalued compared to its peers.
- Examining PulmonxCorp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PulmonxCorp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PulmonxCorp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PulmonxCorp's stock. These opinions can provide insight into PulmonxCorp's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in PulmonxCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for PulmonxCorp Stock analysis
When running PulmonxCorp's price analysis, check to measure PulmonxCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PulmonxCorp is operating at the current time. Most of PulmonxCorp's value examination focuses on studying past and present price action to predict the probability of PulmonxCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PulmonxCorp's price. Additionally, you may evaluate how the addition of PulmonxCorp to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is PulmonxCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PulmonxCorp. If investors know PulmonxCorp will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PulmonxCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 1.909 | Quarterly Revenue Growth 0.297 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of PulmonxCorp is measured differently than its book value, which is the value of PulmonxCorp that is recorded on the company's balance sheet. Investors also form their own opinion of PulmonxCorp's value that differs from its market value or its book value, called intrinsic value, which is PulmonxCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PulmonxCorp's market value can be influenced by many factors that don't directly affect PulmonxCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PulmonxCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if PulmonxCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PulmonxCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.